Abstract: The challenge for the present invention is to provide a catalyst composition restrained from declining in performance over time in purifying an exhaust gas containing an organic compound a silicon compound, a catalyst containing the catalyst composition, and a method for producing the catalyst. This challenge is solved by using a catalyst composition containing zeolite added to precious metal-carried alumina, and the silicon resistance of the catalyst is improved greatly. The amount of acid of the zeolite added is preferably in the range of 0.4 mmol·NH3/g to 1.5 mmol·NH3/g.

Abstract: A method for preparing cracking catalyst. The method comprises making catalyst slurry having a homogeneous distribution of molecular sieve slurry, pseudoboehmite, clay, inorganic acid and aluminum-containing binder; and subsequent spray drying. Inorganic acid is added prior to the addition of pseudoboehmite; addition of molecular sieve is added after the addition of inorganic acid; and a phosphatic dispersant is added during preparation. Compared to conventional methods of preparing FCC catalyst slurry, the inventive catalyst slurry viscosity is decreased and the fluidity thereof is improved, while catalyst anti-friction is maintained. The solid content of the FCC catalyst slurry can be increased to about 40% or more. The gel forming time is significantly reduced with increased productivity and decreased catalyst production cost. Meanwhile, the catalyst has high pore volume and improved micro-reactivity. Overall reactivity performance of the catalyst is also improved.

Abstract: A process for regenerating a used acidic ionic liquid catalyst which has been deactivated by conjunct polymers comprising combining the used catalyst, a metal and a Broensted acid which acts a source of hydrogen in a reaction zone under hydrogenation conditions for a time sufficient to hydrogenate at least a portion of the conjunct polymer is disclosed.

Abstract: Novel ?-diimine metal complexes, particularly iron complexes, having a phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are disclosed. The ?-diimine metal complexes having a phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are produced by forming one of the ?-diimine metal complex imine bonds in the presence of a metal salt or an ?-acylimine metal complex. The ?-diimine metal complexes having phenyl sulfidyl or substituted phenyl sulfidyl metal complexing group are useful for polymerizing or oligomerizing olefins.

Abstract: Activation of a tungsten-containing catalyst using water in a PEM-type fuel cell is described as well as cathode operation of the tungsten-containing catalyst.

Abstract: A catalyst composition and its use for the oxidation of ethane to ethylene and acetic acid which comprises (i) a support, and (ii) in combination with oxygen, the elements molybdenum, vanadium and niobium, optionally tungsten and a component Z, which is one or more metals of Group 14 of the Periodic Table of Elements; a, b, c, d and e represent the gram atom ratios of the elements Mo, W, Z, V and Nb respectively, such that 0<a?1; 0?b<1 and a+b=1; 0.05<c?2; 0<d?2; and 0<e?1.

Abstract: A catalyst having dual functionality for the removal of arsenic and the selective hydrogenation of diolefins from monoolefin-containing hydrocarbon streams that have an arsenic concentration and a diolefin concentration, and processes for making and using such catalyst. The catalyst is a heat treated shaped mixture of a refractory oxide and a Group VIII metal that is overlaid with additional Group VIII metal.

Abstract: A catalyst includes a conductive carrier and catalyst particles. The catalyst particles are supported on the conductive carrier and have a composition represented by formula 1, below. An area of a peak derived from a metal bond of a T-element is 15% or more of an area of a peak derived from an oxygen bond of the T-element in a spectrum obtained by X-ray photoelectron spectroscopic method. PtxRuyTz??(1) where the T-element is at least one element selected from the group consisting of V, Nb and Hf, x is 30 to 60 at. %, y is 20 to 50 at. % and z is 5 to 50 at. %.

Abstract: Use of physical vapor deposition methodologies to deposit nanoscale gold on activating support media makes the use of catalytically active gold dramatically easier and opens the door to significant improvements associated with developing, making, and using gold-based, catalytic systems. The present invention, therefore, relates to novel features, ingredients, and formulations of gold-based, heterogeneous catalyst systems generally comprising nanoscale gold deposited onto a nanoporous support.

Abstract: A method of producing activated carbon fibers (ACFs) includes the steps of providing a natural carbonaceous precursor fiber material, blending the carbonaceous precursor material with a chemical activation agent to form chemical agent-impregnated precursor fibers, spinning the chemical agent-impregnated precursor material into fibers, and thermally treating the chemical agent-impregnated precursor fibers. The carbonaceous precursor material is both carbonized and activated to form ACFs in a single step. The method produces ACFs exclusive of a step to isolate an intermediate carbon fiber.

Abstract: The invention relates to novel 2-ethyl-4,6-dimethylphenyl-substituted spirocyclic tetramic acid derivatives of the formula (I) in which A, B and G are as defined above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, and also to selective herbicidal compositions comprising firstly the 2-ethyl-4,6-dimethylphenyl-substituted spirocyclic tetramic acid derivatives of the formula (I) (where G may also be hydrogen) and secondly at least one crop plant compatibility-improving compound.

Abstract: Articles are provided including a base substrate having a layer of an oriented cubic oxide material with a rock-salt-like structure layer thereon, and, a layer of epitaxial titanium nitride upon the layer of an oriented cubic oxide material having a rock-salt-like structure. Such articles can further include thin films of high temperature superconductive oxides such as YBCO upon the layer of epitaxial titanium nitride or upon a intermediate buffer layer upon the layer of epitaxial titanium nitride.

Abstract: Among many things, in some embodiments, dual-function additives that enhance fluid loss control and the stability of viscoelastic surfactant fluids, and their associated methods of use in subterranean formations, are provided. In one embodiment, the methods comprise: providing a viscoelastic surfactant fluid that comprises an aqueous base fluid, a viscoelastic surfactant, and a dual-function additive that comprises a soap component; and introducing the viscoelastic surfactant fluid into at least a portion of a subterranean formation.

Abstract: Acidic treatment fluids used in industrial and/or subterranean operations, and more particularly, acidic treatment fluids comprising clarified xanthan gelling agents, and methods of use in industrial and/or subterranean operations, are provided. In one embodiment, the methods comprise: providing an acidic treatment fluid that comprises an aqueous base fluid, an acid, and a gelling agent that comprises clarified xanthan; and introducing the acidic treatment fluid into a portion of a subterranean formation.

Abstract: Acidic treatment fluids used in industrial and/or subterranean operations, and more particularly, acidic treatment fluids comprising clarified xanthan gelling agents, and methods of use in industrial and/or subterranean operations, are provided. In one embodiment, the acidic treatment fluids comprise an aqueous base fluid, an acid, and a gelling agent comprising clarified xanthan.

Abstract: A method of treating an earth formation that includes injecting at least one lipophilic monomer into the earthen formation; wherein the at least one lipophilic monomer is selected from epoxide-functionalized derivative of soybean oil, linseed oil, rapeseed oil, cashew nut shell oil; perilla oil, tung oil, oiticia oil, safflower oil, poppy oil, hemp oil, cottonseed oil, sunflower oil, high-oleic triglycerides, triglycerides of euphorbia plants, peanut oil, olive oil, olive kernel oil, almond oil, kapok oil, hazelnut oil, apricot kernel oil, beechnut oil, lupine oil, maize oil, sesame oil, grapeseed oil, lallemantia oil, castor oil, herring oil, sardine oil, menhaden oil, whale oil, and tall oil, injecting at least one crosslinking agent into the earthen formation; wherein the at least one crosslinking agent comprises at least one primary amine; and allowing the lipophilic monomer and the crosslinking agent to react in the earth formation is disclosed.

Abstract: A method of controlling the pressure of a casing annulus in a subterranean well that includes injecting into the casing annulus a composition including a base fluid and a polymer coated colloidal solid material. The polymer coated colloidal solid material includes: a solid particle having an weight average particle diameter (d50) of less than two microns, and a polymeric dispersing agent coated onto the surface of the solid particle during the cominution (i.e. grinding) process utilized to make the colloidal particles. The polymeric dispersing agent may be a water soluble polymer having a molecular weight of at least 2000 Daltons. The solid particulate material may be selected from materials having of specific gravity of at least 2.

Abstract: In one embodiment, the present invention provides a silicone-tackifier matrix composition that comprises at least one silicone polymer component, at least one tackifying agent, and at least one curing agent and/or at least one cross linking agent.

Abstract: The passage of a container along a conveyor is lubricated by applying to the container or conveyor a composition comprising a water-miscible silicone material wherein the composition comprises a stoichiometric amount of an organic acid. The compatibility of the lubricating composition with polyethylene terephthalate is increased because of the presence of a stoichiometric amount of acid.

Abstract: The invention relates to sheet metal or a sheet metal blank provided with a lubricant coating, especially an anti-corrosion oil of the Pre-Lube or Dry Lube variety. The sheet metal or sheet metal blank comprises a layer which is formed by applying a solution containing an organic phosphoric acid ester to the metal surface of the sheet metal. Sheet metal provided with said coating has excellent tribological properties.

Abstract: A lubricating composition comprising an oil of lubricating viscosity, 1 to 1000 parts per million by weight of titanium in the form of an oil-soluble titanium-containing material, and at least one additional lubricant additive provides beneficial effects on properties such as deposit control, oxidation, and filterability in engine oils.

Abstract: Compositions of an ester-containing phenolic antioxidant seal-conditioning agent represented by the formula and a second seal-conditioning agent selected from sulfolanes, benzyl ester, lactones, nitriles, and other ester-containing phenolic anitoxidant seal-conditioning agents, serve to protect the integrity of elastomeric materials in contact with lubricants.

Abstract: Modified polysaccharide polymers for use as anti-scalant and dispersant. The polymers are useful in compositions used in aqueous systems. The modified polysaccharides are also useful in detergent formulations, water treatment, dispersants and oilfield applications and as fiberglass binders. Such applications include a modified polysaccharide having up to about 70 mole % carboxyl groups per mole of polysaccharide ASU and up to about 20 mole % aldehyde groups per mole of polysaccharide ASU. The applications can also include a blend of modified polysaccharides and other synthetic polymers.

Abstract: Process for making a functionalized substrate in the form of a water-soluble film carrying a coating of a functional composition, the process comprising applying to at least one side of the film an aqueous solution comprising one or more functional materials to form the coating wherein the coating is formed from a plurality of layers in a stepwise manner and/or the aqueous solution comprises a film insolubilizer agent.

Abstract: The present invention relates to a process for preparing a solid laundry detergent composition comprising: (a) from 1 wt % to 40 wt % light density silicate salt having a bulk density of less than 200 g/l and a weight average particle size of less than 300 micrometers; (b) from 5 wt % to 60 wt % detersive surfactant; (c) from 0 wt % to 50 wt % carbonate salt; (d) from 0 wt % to 40 wt % sulphate salt; (e) from 0 wt % to 30 wt % phosphate builder; (f) from 0 wt % to 5 wt %% zeolite builder; and (g) from 0 wt % to 15 wt % water; wherein the composition has a bulk density of 600 g/l or less.

Abstract: A mixture of surfactant and co-surfactant which is an amphiphilic polymer with the formula:

Abstract: [PROBLEMS] The present invention provides a novel cleaner having bacteria-proof, fungi-proof and algae-proof effects, which is added to a reaction thermostat using water as medium in scientific apparatus, particularly a thermostatic water bath in an automatic analyzer. [SOUTLIN] A cleaner for a thermostatic water bath, which comprises a quaternary ammonium salt as shown by the general formula [1] described below and/or a preservative agent having amphoteric surface activity, and a surface active agent, wherein R1 to R4 independently represent an alkyl group, provided that at least one among R1 to R4 is an alkyl group having 8 to 18 carbon atoms, and at least one among them is a lower alkyl group having 1 to 3 carbon atoms; and X? represents an anion derived from a carboxylic acid having two or more carbon atoms; and a cleaning method of a thermostatic water bath, wherein the cleaner is added to a thermostatic water bath.

Abstract: A kit of parts comprising two or more protein kinase substrate polypeptides, each said substrate polypeptide comprising a specificity conferring portion (which is different for each said kinase substrate polypeptide) and a phosphorylatable portion, wherein the phosphorylatable portions of each polypeptide are capable of being bound in a phosphorylation state-sensitive manner by the same specific binding partner, for example and antibody preparation, and wherein the said specific binding partner is not an antibody specific for phosphotyrosine, phosphoserine or phosphothreonine. The phosphorylatable portion preferably comprises the amino acid sequence LSFAEPG.

Abstract: It is intended to provide a model animal faithfully reproducing the pathogenic conditions of spinal and bulbar muscular atrophy, a method of screening a remedy for polyglutamine disease using the same, and a remedy for spinal and bulbar muscular atrophy. Namely, a nonhuman animal having the following characteristics (1) to (5) in its conditions or pathological findings: (1) showing progressive myoatrophy; (2) showing lowering in muscular power; (3) in immunostaining with the use of an anti-polyglutamine antibody, showing nuclear diffuse staining and nuclear inclusions; (4) in immunostaining with the use of an anti-androgen receptor antibody, showing nuclear diffuse staining and nuclear inclusions; and (5) showing a neurogenic change. A remedy for polyglutamine disease is screened by administering a test substance to this nonhuman animal and examining changes in its conditions or pathological findings.

Abstract: Ac-Sar-Gly-Val-D-allo-Ile-Thr-Nva-Ile-Arg-ProNHCH2CH3 Crystalline Form 1, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Abstract: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.

Abstract: Pharmaceutical compositions containing NK2 antagonists are described, useful for the treatment of infantile colics.

Abstract: Nonadepsipeptides and methods for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases are described.

Abstract: The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.

Abstract: A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.

Abstract: The present invention relates to the use of substances with oxytocin activity against climacteric disorders or similar symptoms due to dysfunction in the ovaries. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against climacteric disorders.

Abstract: The invention relates to a C5a receptor antagonist of structure (I), wherein X1 is a radical having a mass of about 1-300 and stands for R5-, R5-CO—, R5-N(R6)-CO—, R5-O—CO—, R5-SO2—, R5-N(R6)-SO2—, R5-N(R6)-, R5-N(R6)-CS—, R5-N(R6)-C(NH)—, R5-CS—, R5-P(O)OH—, R5-B(OH)— or R5-CH?N—O—CH2—CO—, wherein R5/R6 represent H, F, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, arylalkyl, substituted arylalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, alkoxy, alkoxyalkyl, substituted alkoxyalkyl, aryloxyalkyl or substituted aryloxyalkyl; X2=radical (biological bonding properties of a mimicrying phenylalanine unit); X3/X4=spacer (amino acids, amino-acid analogs and amino-acid derivatives); X5=radical (biological bonding properties of a mimicrying cyclohexylalanine or homoleucine unit); X6=radical (biological bonding properties of a mimicrying tryptophan unit); X7=radical (biological bonding properties of a mimicrying

Abstract: An object of the present invention is to provide an antioxidant composition that is effective in the living body against active oxygen species produced in the body. The present invention provides an antioxidant composition having the effect of suppressing three active oxygen species, i.e. hypochlorite radicals, hydroxyl radicals, and peroxynitrite radicals, with respect to active oxygen species produced in the body, the antioxidant composition comprising a mixture in which at least 20 mg of vitamin C (L-ascorbic acid or sodium L-ascorbate) as an agent to scavenge peroxynitrite active oxygen, and at least 2 mg of caffeic acid analogue compound(s), at least 10 mg of polyphenyol compound(s) or at least 1.5 mg of carotenoid compound(s) as an agent to scavenge hydroxyl radical active oxygen are combined with 100 mg of histidine-containing dipeptide, or sulfur-containing amino acids or analogues thereof obtained from animal extract as an agent for scavenging hypochlorite active oxygen.

Abstract: The present invention concerns powders containing a pharmaceutical active substance and a combination of excipients comprising at least one 1,4 O-linked saccharose derivative selected from the compounds: 1,4 O-linked D-Gal-saccharose (lactosucrose), 1,4 O-linked D-Glu-saccharose (glucosyl sucrose), or 1,4 O-linked Glu-Glu-saccharose (maltosyl sucrose) in combination with at least one further excipient. The other excipient is preferably an amino acid, a peptide and/or a mono-, di- and/or oligosaccharide, wherein the oligosaccharide may be a second 1,4 O-linked saccharose derivative, provided that this is different from the first.

Abstract: The invention relates to synthetic tetrapeptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. An exemplary synthetic tetrapeptide amide of the invention is D-Phe-D-Phe-D-Leu-(?-Me) D-Lys-[4-Amidinohomopiperazine amide]: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.

Abstract: The present invention relates to inhibitors of post-proline cleaving enzymes, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention are improved over those in the prior art by selection of particular classes of sidechains in the P1 and/or P2 position of the inhibitor. The compounds of the present invention can have a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease.

Abstract: The present invention relates to C-Glycosylisoflavones having alkylaminoalkoxyl substituent and pharmaceutically acceptable salts thereof, a process for the preparation thereof, pharmaceutical compositions comprising an effective amount of a compound of the formula (I), and to the use of these compounds or compositions for the treatment or prevention of cardio- and cerebrovascular diseases, in particular for the treatment of various cardiocerebral hypoxic-ischemic diseases, for the treatment or prevention of diabetes mellitus and complications thereof, and for the treatment or prevention of chemical poisoning, in particular alcoholism.

Abstract: The present invention describes natamycin comprising needle shaped crystals.

Abstract: Compositions of matter for treating cancer patients are used to prevent or limit cardiotoxicity during or after treatment with anthracycline drugs, and to prevent or lower resistance to anthracycline drugs, both of which are believed to be caused by the human enzyme carbonyl reductase. Preferred embodiments comprise a pharmaceutical composition comprising compounds having halogenated (or pseudo-halogenated) aryl groups, preferably halogenated (or pseudo-halogenated) arylcyanooximes or phenylcyanooximes and derivatives or analogs thereof, including those comprising —CL or —F, or other substituents on an aryl/phenyl ring. The preferred composition of arylcyanooxime(s) may be administered in a pharmaceutical composition also comprising at least one anthracycline compound, or may be administered separately from the at least one anthracycline compound.

Abstract: Methods of treatment and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia, and myelodysplastic syndrome. The methods of treatment and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analog. Preferred methods of treatment and pharmaceutical combinations employ gemtuzumab ozogamicin, daunorubicin, and cytarabine.

Abstract: The present invention relates to a conjugate that includes a nucleic acid ligand bound to a controlled release polymer system, a pharmaceutical composition that contains the conjugate, and methods of treatment using the conjugate. The controlled release polymer system includes an agent such as a therapeutic, diagnostic, prognostic, or prophylactic agent. The nucleic acid ligand that is bound to the controlled release polymer system, binds selectively to a target, such as a cell surface antigen, and thereby delivers the controlled release polymer system to the target.

Abstract: The present invention provides multiple-promoter expression cassettes for simultaneous delivery of RNAi, preferably to mammalian cells in vivo.

Abstract: The present invention relates to prevention and treatment of strokes and ischemic diseases and to post-ischemic therapeutic treatment. The invention furthermore relates to the use of a growth factor or nucleic acids ensuring increased expression of a growth factor for treating, more particularly restoring the function of ischemic tissue, in particular muscles such as myocardium and skeletal muscles.

Abstract: The present invention relates to a method for determining absorption of cobalamin or analogues thereof in an individual comprising (ii providing two blood samples from said individual, wherein the first sample comprises said individual's blood prior to ingestion by said individual of non-radioactive cobalamin or an analogue thereof and the second sample comprises said individual's blood after said ingestion, (ii) determining the concentration of cobalamin or analogue thereof in the first sample, (iii) determining the concentration of cobalamin or analogue thereof in the second sample by treating complexes of cobalamin or analogue thereof and one or more carrier proteins with one or more enzymes to release cobalamin or analogue thereof from said one or more carrier proteins, and (iv) determining, on the basis of comparison of said concentrations in said two samples, whether said cobalamin or analogue thereof has been absorbed in the blood stream.

Abstract: Compounds of the formula: and compositions containing one or more such compounds, the compositions preferably being suitable for topical application to the skin.